What is the recommended prescribing regimen for inclisiran, including dosing schedule, patient selection criteria, monitoring parameters, and follow‑up in clinical practice?

Inclisiran Prescription in Clinical Practice

Inclisiran should be prescribed at 284 mg subcutaneously at baseline, 3 months, then every 6 months thereafter, as an adjunct to maximally tolerated statin therapy in adults with established ASCVD or heterozygous familial hypercholesterolemia who require additional LDL-C lowering. 1, 2

Dosing Regimen

The FDA-approved dosing schedule is straightforward and represents inclisiran's primary clinical advantage:

• Initial dose: 284 mg subcutaneous injection at Day 0
• Second dose: 284 mg at Day 90 (3 months)
• Maintenance doses: 284 mg every 6 months thereafter 2

This twice-yearly maintenance dosing after the loading phase offers a significant adherence advantage over PCSK9 monoclonal antibodies, which require injections every 2-4 weeks 1.

Patient Selection Criteria

FDA-Approved Indications

Inclisiran is indicated for adults with:

1. Heterozygous familial hypercholesterolemia (HeFH), OR
2. Established atherosclerotic cardiovascular disease (ASCVD)

Who require additional LDL-C lowering beyond maximally tolerated statin therapy 1, 2

Specific Clinical Scenarios for Inclisiran Use

PCSK9 monoclonal antibodies remain the preferred first-line PCSK9 inhibitor due to proven cardiovascular outcomes benefits in FOURIER and ODYSSEY Outcomes trials 1. However, inclisiran should be specifically considered in:

• Poor adherence to PCSK9 mAbs: Patients with documented non-adherence to biweekly or monthly injections 1
• Adverse effects from both PCSK9 mAbs: Patients who have failed both evolocumab and alirocumab 1
• Inability to self-inject: Patients requiring clinician administration 1
• Preference for less frequent dosing: Patients who prioritize convenience despite similar efficacy 1

Treatment Goals

According to 2022 ACC guidelines, target:

• LDL-C reduction ≥50% from baseline, AND
• LDL-C <70 mg/dL in ASCVD patients (not very high risk)
• LDL-C <55 mg/dL in very high-risk ASCVD patients
• LDL-C <100 mg/dL in HeFH without ASCVD 3

Expected Efficacy

Inclisiran demonstrates robust LDL-C lowering:

• Mean LDL-C reduction: 50.5-50.7% at Day 510 in pooled phase 3 trials 1
• LDL-C reduction apparent within 14 days of first dose 2
• Sustained reductions of 38-51% observed 30-180 days post-dose 2
• Real-world data shows 44.7% reduction after first dose, 40.8% after second dose 4

Important caveat: Inclisiran produces approximately 10% less LDL-C reduction compared to PCSK9 monoclonal antibodies in similarly designed trials 1. This should be factored into treatment decisions for patients requiring maximal LDL-C lowering.

Monitoring Parameters

Baseline Assessment

• LDL-C level (must be ≥70 mg/dL for ASCVD patients or elevated for HeFH)
• Current lipid-lowering therapy (document maximally tolerated statin dose)
• Renal function (no dose adjustment needed, but document baseline)
• Hepatic function (no dose adjustment for mild-moderate impairment; not studied in severe impairment) 2

Follow-up Monitoring

• LDL-C levels: Check at 3-6 months after initiation, then at 12 months 5
• Adherence to dosing schedule: Verify second dose given at 3 months, subsequent doses every 6 months
• Injection site reactions: Monitor for mild reactions (pain, erythema) - occur in 5% vs 0.7% placebo 1
• No routine laboratory monitoring required beyond lipid panels 5

Real-world data demonstrates excellent adherence: 96.8% received second dose, 89.5% received third dose, with 95.5% receiving second dose within 5 months 4.

Administration Considerations

Practical Issues

• Must be administered by a healthcare provider (not self-administered like PCSK9 mAbs)
• Billed under medical benefit rather than pharmacy benefit - verify insurance coverage 1
• Higher first-year cost than PCSK9 mAbs, but cost difference decreases in subsequent years 1
• Patient assistance programs available for eligible patients 1

Special Populations

• Renal impairment: No dose adjustment needed despite 2-3-fold increase in plasma exposure; LDL-C reductions remain similar 2
• Hepatic impairment: No adjustment for mild-moderate impairment; not studied in severe hepatic impairment - avoid use 2
• Pregnancy/nursing: All lipid-lowering drugs contraindicated 5
• No dose adjustments needed based on age, weight, gender, or race 2

Treatment Algorithm Position

When to Use Inclisiran vs. Other Agents

First-line nonstatin therapy: Ezetimibe (proven outcomes, oral, inexpensive) 1

Second-line therapy: PCSK9 mAb preferred (proven CV outcomes) 1

Inclisiran as alternative to PCSK9 mAb when:

• Adherence concerns with frequent injections
• Intolerance to both PCSK9 mAbs
• Patient preference for biannual dosing
• Inability to self-inject 1

Do NOT combine inclisiran with PCSK9 mAb - no evidence for additive benefit, use one or the other 1

Referral Indications

Refer to lipid specialist if:

• Patient fails to achieve <50% LDL-C reduction or LDL-C ≥70 mg/dL on maximally tolerated statin + ezetimibe + PCSK9 inhibitor (mAb or inclisiran) 1
• Considering inclisiran in patient with continued inadequate LDL-C control 1
• Suspected homozygous FH 1

Critical Limitations

Cardiovascular outcomes data are pending. Unlike PCSK9 mAbs, inclisiran lacks completed cardiovascular outcomes trials. ORION-4 and VICTORION-2P trials are ongoing, with completion expected in 2026-2027 1. The drug's approval is based on LDL-C reduction as a surrogate endpoint, with the assumption that similar LDL-C lowering will translate to similar CV risk reduction 2.

Safety Profile

• Injection site reactions: 5% (predominantly mild, none severe or persistent) 1
• Overall adverse events similar to placebo 1
• Anti-drug antibodies: 5% developed during treatment, 2% had persistent response; no clinically significant effect on efficacy or safety over 18 months, but long-term consequences unknown 2
• No drug-drug interactions - not a substrate, inhibitor, or inducer of CYP450 or transporters 2
• No effect on QT interval 2